ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Compared to imatinib, dasatinib enables patients with chronic phase CML to achieve faster and deeper treatment responses (i.e., median time to major molecular response (MMR) for dasatinib arm was 15 versus 36 months for the imatinib arm, and BCR-ABL transcript 4.5-log reduction was achieved by 17 versus 8% of patients by 24 months, respectively) [25].